Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Ipilimumab, and Cabozantinib in Untreated Renal Cell Carcinoma Brain Metastases
NCT05048212Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab, cabozantinib in renal cell carcinoma (RCC), brain metastases, sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2022; status: recruiting.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)brain metastases
Beyond the preview
Go deeper on NCT05048212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048212.